Acquiring Company
Ambros Therapeutics
Acquired Company
Werewolf Therapeutics
IrvineWatertownBiotechnologyHealth CareTherapeuticsBiotechnologyHealthcareHealth CareTherapeuticsDescription
Werewolf Therapeutics and Ambros Therapeutics have entered a definitive all-stock merger agreement to form a Nasdaq-listed biotechnology company. The merger will enable the combined entity to focus on developing neridronate for Complex Regional Pain Syndrome Type 1. The transaction is expected to close by the first quarter of 2027, subject to appropriate approvals. Existing shareholders will receive a stake in the new company and potential value tied to legacy assets.
Quick answer
Ambros Therapeutics is acquiring Werewolf Therapeutics, announced August 21, 2026. Ambros Therapeutics is based in Irvine, California, United States.
- How much did Ambros Therapeutics pay for Werewolf Therapeutics?
- The deal value was not disclosed.
- What does Ambros Therapeutics do?
- Ambros Therapeutics is a biotech firm focused on developing a non-opioid pain medicine for Complex Regional Pain Syndrome type 1 (CRPS-1).
- Where are Ambros Therapeutics and Werewolf Therapeutics based?
- Ambros Therapeutics is based in Irvine, California, United States. Werewolf Therapeutics is based in Watertown, Massachusetts, United States.
- Who are the decision-makers at Ambros Therapeutics?
- Fundz holds 2 contacts at Ambros Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Healthcare
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Yarrow Bioscience completes merger with VYNE Therapeutics (July 27, 2026)
- SpyGlass Pharma, Inc. Acquires Santen Holdings US, Inc. (October 1, 2026)
- Aethlon Medical to merge with North Immunology (September 17, 2026)
- Yarrow Bioscience, Inc. Completes Merger with Yarrow Bioscience Operating Company Corp. (September 10, 2026)
- Cureety acquires Reimagine Care for oncology (September 2, 2026)
- BioCryst acquires Astria Therapeutics for drug access (August 29, 2026)
Who to call at Ambros Therapeutics, and when
When Ambros Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ambros Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ambros Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ambros Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ambros Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Werewolf Therapeutics?
Werewolf Therapeutics was acquired by Ambros Therapeutics, based in Irvine. The deal was reported on August 21, 2026. Ambros Therapeutics is a biotech firm focused on developing a non-opioid pain medicine for Complex Regional Pain Syndrome type 1 (CRPS-1). Ambros Therapeutics is privately held and operates in Biotechnology.
When did Ambros Therapeutics acquire Werewolf Therapeutics?
Ambros Therapeutics's acquisition of Werewolf Therapeutics was reported on August 21, 2026. Werewolf Therapeutics and Ambros Therapeutics have entered a definitive all-stock merger agreement to form a Nasdaq-listed biotechnology company. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Werewolf Therapeutics do?
Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is publicly traded (HOWL), operating in Biotechnology, and is based in Watertown.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.